
Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer

SUPPLEMENTARY MATERIALS

DMSO

Dabrafenib (2.5 µM)



**Supplementary Figure 1: High magnification images of H1666 cells treated with DMSO or Dabrafenib.** High magnification images of Figure 6C reveal that H1666 cells treated with Dabrafenib for one week are less densely distributed compared to the DMSO group.